{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:13:48Z","timestamp":1765995228943,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec>\n                <jats:title>Background and aims<\/jats:title>\n                <jats:p>Micro-elimination projects targeted to specific hepatitis\u00a0C virus (HCV) risk populations have been successful. Systematic identification of persons with HCV viremia, regardless of risk group, based on already available laboratory records may represent an effective macroelimination approach to achieve global HCV elimination.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Persons with a\u00a0last positive HCV-RNA PCR result between 2008\u20132020 in the reference virology laboratories in eastern Austria were identified. First, (i)\u00a0we described their demographic characteristics, (ii)\u00a0we systematically recalled persons to the respective centers and (iii)\u00a0started antiviral treatment if HCV-RNA viremia was confirmed, and (iv)\u00a0recorded sustained virologic response (SVR). This interim report includes the preliminary results from 8 participating centers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the study period 22,682 persons underwent HCV-RNA PCR testing, 11,216 (49.4%) were  positive at any point in time, and 6006 (26.5%) showed detectable HCV-RNA at the last PCR test, suggesting ongoing HCV viremia.<\/jats:p>\n                <jats:p>At the time of this interim report, 2546\/6006 HCV-RNA PCR(+) persons were evaluated: 443\/2546 (17.4%) had died, 852\/2546 (33.5%) had invalid contact data, and 547\/2546 (21.5%) had achieved SVR between data retrieval and recall. Contact could be established in 236\/704 (33.5%) of the remaining target population with 97\/236 (41.1%) presenting at the clinic for treatment evaluation. Ultimately, 71\/236 (30.1%) started antiviral treatment and SVR was documented in 47\/71 (66.2%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This ELIMINATE project based on systematic assessment of HCV-RNA PCR-records, identified 6006 persons with potential persisting HCV viremia. Invalid contact data and missed visits for treatment evaluation were the main barriers towards HCV elimination within this project. Importantly, many subjects with HCV viremia lost to follow-up were successfully linked to care and started antiviral treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00508-023-02275-4","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T12:02:38Z","timestamp":1695988958000},"page":"278-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["ELIMINATE: a\u00a0PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria"],"prefix":"10.1007","volume":"136","author":[{"given":"Caroline","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Dorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Jachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Hartl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Chromy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Weseslindtner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Pfisterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Hennlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"St\u00fcckler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Strassl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Voill-Glaninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"H\u00fcbl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Willheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"K\u00f6hrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Jansen-Skoupy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Tomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Krugluger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Madl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"Balcar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Semmler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Burghart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Antonitsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Laferl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesselina","family":"Kurteva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Traugott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Hind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Wenisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelrahman","family":"Aburaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Sebesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Rothweiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Remetic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gschwantler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Maieron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"issue":"5","key":"2275_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/jvh.13665","volume":"29","author":"D Chromy","year":"2022","unstructured":"Chromy\u00a0D, Bauer\u00a0DJM, Simbrunner\u00a0B, Jachs\u00a0M, Hartl\u00a0L, Schwabl\u00a0P, et al. The \u201cViennese epidemic\u201d of acute HCV in the era of direct-acting antivirals. J\u00a0Viral Hepat. 2022;29(5):385\u201394.","journal-title":"J Viral Hepat"},{"key":"2275_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00472-6","author":"Polaris Observatory HCV Collaborators","year":"2022","unstructured":"Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022; https:\/\/doi.org\/10.1016\/S2468-1253(21)00472-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"2275_CR3","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/hep.31462","volume":"73","author":"G Semmler","year":"2021","unstructured":"Semmler\u00a0G, Binter\u00a0T, Kozbial\u00a0K, Schwabl\u00a0P, Hametner-Schreil\u00a0S, Zanetto\u00a0A, et al. Noninvasive risk stratification after HCV eradication in patients with advanced chronic liver disease. Hepatology. 2021;73(4):1275\u201389.","journal-title":"Hepatology"},{"issue":"4","key":"2275_CR4","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jhep.2021.11.025","volume":"76","author":"G Semmler","year":"2022","unstructured":"Semmler\u00a0G, Meyer\u00a0EL, Kozbial\u00a0K, Schwabl\u00a0P, Hametner-Schreil\u00a0S, Zanetto\u00a0A, et al. HCC risk stratification after cure of hepatitis\u00a0C in patients with compensated advanced chronic liver disease. J\u00a0Hepatol. 2022;76(4):812\u201321.","journal-title":"J Hepatol"},{"issue":"1","key":"2275_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.29814","volume":"68","author":"J Berenguer","year":"2018","unstructured":"Berenguer\u00a0J, Gil-Martin \u00c1, Jarrin\u00a0I, Moreno\u00a0A, Dominguez\u00a0L, Montes\u00a0M, et al. All-oral direct-acting antiviral therapy against hepatitis\u00a0C virus (HCV) in human immunodeficiency virus\/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings. Hepatology. 2018;68(1):32\u201347.","journal-title":"Hepatology"},{"key":"2275_CR6","volume-title":"Global health sector strategy on viral hepatitis 2016\u20132021","author":"WHO","year":"2016","unstructured":"WHO. Global health sector strategy on viral hepatitis 2016\u20132021. Geneva: World Health Organization; 2016."},{"key":"2275_CR7","unstructured":"HCV prevalence calculations based on IHME. 2023. https:\/\/www.globalhep.org\/country-progress\/austria. Accessed 23.08.2021."},{"key":"2275_CR8","unstructured":"Austrian Agency for Health and Food Safety Ltd. 2020. https:\/\/www.ages.at\/en\/ages\/basics\/#downloads. Accessed 01.09.2022."},{"issue":"4","key":"2275_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/liv.14399","volume":"40","author":"C Schmidbauer","year":"2020","unstructured":"Schmidbauer\u00a0C, Chromy\u00a0D, Schmidbauer\u00a0V, Bauer\u00a0D, Apata\u00a0M, Nguyen\u00a0D, et\u00a0al. Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. Liver Int. 2020;40(4):787\u201396.","journal-title":"Liver Int"},{"issue":"12","key":"2275_CR10","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.healthpol.2018.10.005","volume":"122","author":"M Silbernagl","year":"2018","unstructured":"Silbernagl\u00a0M, Slamanig\u00a0R, Fischer\u00a0G, Brandt\u00a0L. Hepatitis\u00a0C infection and psychiatric burden in two imprisoned cohorts: young offenders and opioid-maintained prisoners. Health Policy. 2018;122(12):1392\u2013402.","journal-title":"Health Policy"},{"issue":"1","key":"2275_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12889-017-4102-5","volume":"17","author":"K Page","year":"2017","unstructured":"Page\u00a0K, Yu\u00a0M, Cohen\u00a0J, Evans\u00a0J, Shumway\u00a0M, Riley\u00a0ED. HCV screening in a\u00a0cohort of HIV infected and uninfected homeless and marginally housed women in San Francisco, California. BMC Public Health. 2017;17(1):171.","journal-title":"BMC Public Health"},{"issue":"13\u201314","key":"2275_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00508-021-01898-9","volume":"133","author":"M Jachs","year":"2021","unstructured":"Jachs\u00a0M, Binter\u00a0T, Chromy\u00a0D, Schalk\u00a0H, Pichler\u00a0K, Bauer\u00a0D, et\u00a0al. Outcomes of an HCV elimination program targeting the Viennese MSM population. Wien Klin Wochenschr. 2021;133(13\u201314):635\u201340.","journal-title":"Wien Klin Wochenschr"},{"issue":"3","key":"2275_CR13","doi-asserted-by":"publisher","first-page":"e0229239","DOI":"10.1371\/journal.pone.0229239","volume":"15","author":"C Schmidbauer","year":"2020","unstructured":"Schmidbauer\u00a0C, Schubert\u00a0R, Sch\u00fctz\u00a0A, Schwanke\u00a0C, Luhn\u00a0J, Gutic\u00a0E, et al. Directly observed therapy for HCV with glecaprevir\/pibrentasvir alongside opioid substitution in people who inject drugs-first real world data from Austria. PLoS ONE. 2020;15(3):e229239.","journal-title":"PLoS ONE"},{"issue":"6","key":"2275_CR14","doi-asserted-by":"publisher","first-page":"e0252274","DOI":"10.1371\/journal.pone.0252274","volume":"16","author":"C Schmidbauer","year":"2021","unstructured":"Schmidbauer\u00a0C, Schwarz\u00a0M, Sch\u00fctz\u00a0A, Schubert\u00a0R, Schwanke\u00a0C, Gutic\u00a0E, et al. Directly observed therapy at opioid substitution facilities using sofosbuvir\/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy. PLoS ONE. 2021;16(6):e252274.","journal-title":"PLoS ONE"},{"issue":"9\u201310","key":"2275_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s00508-020-01790-y","volume":"133","author":"L Steininger","year":"2021","unstructured":"Steininger\u00a0L, Chromy\u00a0D, Bauer\u00a0D, Simbrunner\u00a0B, Binter\u00a0T, Schwabl\u00a0P, et al. Direct patient-physician communication via a\u00a0hepatitis\u00a0C hotline facilitates treatment initiation in patients with poor adherence. Wien Klin Wochenschr. 2021;133(9\u201310):452\u201360.","journal-title":"Wien Klin Wochenschr"},{"issue":"05","key":"2275_CR16","first-page":"P61","volume":"58","author":"M Schwarz","year":"2020","unstructured":"Schwarz\u00a0M, Gremmel\u00a0S, Wurz\u00a0M, Schmidbauer\u00a0C, Gutic\u00a0E, Lang\u00a0T, et\u00a0al. \u201cLet\u2019s end hepatitis\u00a0C in Vienna\u201d\u2014the first HCV elimination program targeting homeless and people without medical insurance in Vienna. Z\u00a0Gastroenterol. 2020;58(05):P61.","journal-title":"Z Gastroenterol"},{"issue":"1","key":"2275_CR17","doi-asserted-by":"publisher","first-page":"100319","DOI":"10.1016\/j.jve.2023.100319","volume":"9","author":"M Schwarz","year":"2023","unstructured":"Schwarz\u00a0M, Schwarz\u00a0C, Sch\u00fctz\u00a0A, Schwanke\u00a0C, Krabb\u00a0E, Schubert\u00a0R, et al. Combining treatment for chronic hepatitis\u00a0C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy. J\u00a0Virus Erad. 2023;9(1):100319.","journal-title":"J Virus Erad"},{"key":"2275_CR18","unstructured":"Neunerhaus. Neunerhaus. 2021. https:\/\/www.neunerhaus.at. Accessed 10.09.2022."},{"issue":"12","key":"2275_CR19","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/jvh.13746","volume":"29","author":"L Hartl","year":"2022","unstructured":"Hartl\u00a0L, Jachs\u00a0M, Bauer\u00a0D, Simbrunner\u00a0B, Chromy\u00a0D, Binter\u00a0T, et al. An HCV hotline facilitates Hepatitis C elimination during the COVID-19 pandemic. J\u00a0Viral Hepat. 2022;29(12):1062\u201372. https:\/\/doi.org\/10.1111\/jvh.13746.","journal-title":"J Viral Hepat"},{"issue":"10","key":"2275_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.drugpo.2015.07.007","volume":"26","author":"J Grebely","year":"2015","unstructured":"Grebely\u00a0J, Bruggmann\u00a0P, Treloar\u00a0C, Byrne\u00a0J, Rhodes\u00a0T, Dore\u00a0GJ, et\u00a0al. Expanding access to prevention, care and treatment for hepatitis\u00a0C virus infection among people who inject drugs. Int J Drug Policy. 2015;26(10):893\u20138.","journal-title":"Int J Drug Policy"},{"issue":"12","key":"2275_CR21","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1007\/s42399-020-00588-3","volume":"2","author":"C Stasi","year":"2020","unstructured":"Stasi\u00a0C, Silvestri\u00a0C, Voller\u00a0F. Update on hepatitis C epidemiology: unaware and untreated infected population could be the key to elimination. SN Compr Clin Med. 2020;2(12):2808\u201315. https:\/\/doi.org\/10.1007\/s42399-020-00588-3.","journal-title":"SN Compr Clin Med"},{"key":"2275_CR22","unstructured":"Coalition for Global Hepatitis Elimination. Hep C elimination tool. 2021. https:\/\/www.globalhep.org\/country-progress\/austria. Accessed 12.10.2022."},{"key":"2275_CR23","unstructured":"Statistik Austria. Regionale Gliederungen \u2013 Bundesl\u00e4nder. 2021. https:\/\/www.statistik.at\/web_de\/klassifikationen\/regionale_gliederungen\/bundeslaender\/index.html. Accessed 01.09.2022."},{"issue":"3\u20134","key":"2275_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00508-017-1231-x","volume":"130","author":"D Chromy","year":"2018","unstructured":"Chromy\u00a0D, Schwabl\u00a0P, Bucsics\u00a0T, Scheiner\u00a0B, Strassl\u00a0R, Mayer\u00a0F, et al. Non-invasive liver fibrosis assessment and HCV treatment initiation within a\u00a0systematic screening program in HIV\/HCV coinfected patients. Wien Klin Wochenschr. 2018;130(3\u20134):105\u201314.","journal-title":"Wien Klin Wochenschr"},{"issue":"3","key":"2275_CR25","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hep.24105","volume":"53","author":"ZH Lin","year":"2011","unstructured":"Lin\u00a0ZH, Xin\u00a0YN, Dong\u00a0QJ, Wang\u00a0Q, Jiang\u00a0XJ, Zhan\u00a0SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis\u00a0C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726\u201336.","journal-title":"Hepatology"},{"issue":"12","key":"2275_CR26","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S1473-3099(16)30325-5","volume":"16","author":"L Degenhardt","year":"2016","unstructured":"Degenhardt\u00a0L, Charlson\u00a0F, Stanaway\u00a0J, Larney\u00a0S, Alexander\u00a0LT, Hickman\u00a0M, et\u00a0al. Estimating the burden of disease attributable to injecting drug use as a\u00a0risk factor for HIV, hepatitis\u00a0C, and hepatitis\u00a0B: findings from the global burden of disease study 2013. Lancet Infect Dis. 2016;16(12):1385\u201398.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2275_CR27","doi-asserted-by":"publisher","first-page":"16863","DOI":"10.1038\/s41598-020-74015-x","volume":"10","author":"J Sutton","year":"2020","unstructured":"Sutton\u00a0J, Shahtahmassebi\u00a0G, Ribeiro\u00a0HV, Hanley\u00a0QS. Rural-urban scaling of age, mortality, crime and property reveals a\u00a0loss of expected self-similar behaviour. Sci Rep. 2020;10(1):16863.","journal-title":"Sci Rep"},{"issue":"3","key":"2275_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/23744235.2022.2153914","volume":"55","author":"D Chromy","year":"2023","unstructured":"Chromy\u00a0D, Bauer\u00a0D, Simbrunner\u00a0B, Jachs\u00a0M, Hartl\u00a0L, Schwabl\u00a0P, et\u00a0al. Progress of hepatitis\u00a0C elimination in viennese people living with HIV after two decades of increasing cure rates. Infect Dis. 2023;55(3):189\u201398.","journal-title":"Infect Dis"},{"issue":"2","key":"2275_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14218\/JCTH.2017.00053","volume":"6","author":"A Austria","year":"2018","unstructured":"Austria\u00a0A, Wu\u00a0GY. Occult hepatitis\u00a0C virus infection: a\u00a0review. J\u00a0Clin Transl Hepatol. 2018;6(2):1\u20136.","journal-title":"J Clin Transl Hepatol"},{"issue":"8","key":"2275_CR30","doi-asserted-by":"publisher","first-page":"e0256544","DOI":"10.1371\/journal.pone.0256544","volume":"16","author":"K Pomej","year":"2021","unstructured":"Pomej\u00a0K, Scheiner\u00a0B, Hartl\u00a0L, Balcar\u00a0L, Meischl\u00a0T, Mandorfer\u00a0M, et al. COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a\u00a0tertiary care hospital. PLoS ONE. 2021;16(8):e256544.","journal-title":"PLoS ONE"},{"issue":"1","key":"2275_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"JP Messina","year":"2015","unstructured":"Messina\u00a0JP, Humphreys\u00a0I, Flaxman\u00a0A, Brown\u00a0A, Cooke\u00a0GS, Pybus\u00a0OG, et\u00a0al. Global distribution and prevalence of hepatitis\u00a0C virus genotypes. Hepatology. 2015;61(1):77\u201387.","journal-title":"Hepatology"},{"issue":"7","key":"2275_CR32","doi-asserted-by":"publisher","first-page":"e0200750","DOI":"10.1371\/journal.pone.0200750","volume":"13","author":"B Schaefer","year":"2018","unstructured":"Schaefer\u00a0B, Viveiros\u00a0A, Al-Zoairy\u00a0R, Blach\u00a0S, Brandon\u00a0S, Razavi\u00a0H, et al. Disease burden of hepatitis\u00a0C in the Austrian state of Tyrol\u2014epidemiological data and model analysis to achieve elimination by 2030. PLoS One. 2018;13(7):e200750.","journal-title":"PLoS One"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02275-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-023-02275-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02275-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T11:11:24Z","timestamp":1715166684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-023-02275-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":32,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2275"],"URL":"https:\/\/doi.org\/10.1007\/s00508-023-02275-4","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2023,9,29]]},"assertion":[{"value":"28 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.\u00a0Schwarz received travel support from Gilead, Abbvie, and Gebro; speaking honoraria from Abbvie and Gilead; and payments for consulting from Gilead. D.\u00a0Bauer received travel support from Gilead and AbbVie; speaking honoraria from AbbVie and Siemens and grant support from Gilead and AbbVie. M.\u00a0Jachs served as a\u00a0speaker and\/or consultant for Gilead Sciences. D.\u00a0Chromy served as a\u00a0speaker and\/or consultant and\/or advisory board member for AbbVie, Gilead, and MSD, and received travel support from AbbVie, MSD, ViiV Healthcare, and Gilead. M.\u00a0Schwarz received travel support from MSD, Sandoz, BMS, Abbvie and Gilead; and speaking honoraria from BMS. L.\u00a0Brinkmann received travel support from Merck Sharp & Dohme, Astro Pharma GmbH. J.\u00a0Remetic: Employee of Gilead Sciences. M.\u00a0Gschwantler received grant support from Abbvie, Gilead, and MSD; speaking honoraria from Abbvie, Gilead, Janssen, Roche, Intercept, and MSD; consulting\/advisory board fees from Abbvie, Gilead, Janssen, Roche, Intercept, Norgine, AstraZeneca, Falk, Shionogi and MSD; and travel support from Abbvie and Gilead. A.\u00a0Maieron received grant support from Abbvie and Gilead; speaking honoraria from Abbvie, Gilead, Janssen, Roche, Intercept, and MSD; consulting\/advisory board fees from Abbvie, Gilead, Janssen, Roche, Intercept, Norgine, and MSD; and travel support from Abbvie, Gilead and Roche. T.\u00a0Reiberger received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting\/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead, and Roche. L.\u00a0Dorn, L.\u00a0Hartl, L.\u00a0Weseslindtner, N.\u00a0Pfisterer, B.\u00a0Hennlich, A.\u00a0St\u00fcckler, R.\u00a0Strassl, A.\u00a0Voill-Glaninger, W.\u00a0H\u00fcbl, M.\u00a0Willheim, K.\u00a0K\u00f6hrer, S.\u00a0Jansen-Skoupy, S.\u00a0Tomez, W.\u00a0Krugluger, C.\u00a0Madl, L.\u00a0Balcar, G.\u00a0Semmler, L.\u00a0Burghart, L.\u00a0Antonitsch, G.\u00a0Weidinger, F.\u00a0Riedl, H.\u00a0Laferl, V.\u00a0Kurteva, M.\u00a0Traugott, J.\u00a0Hind, C.\u00a0Wenisch, A.\u00a0Aburaia, C.\u00a0Sebesta, D.\u00a0Schmid and S.\u00a0Rothweiler declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. The data collection in this study was approved by the respective ethics committees of the Medical University of Vienna (EK#1968\/2018), the ethics committee of the city of Vienna (EK#19-175-VK), and the ethics committee for the State of Lower Austria (EK#GS1-EK-4\/624-2019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}